Related Experiment Video
Updated: Jul 10, 2026
Chronic Salmonella Infection Induced Intestinal Fibrosis
Published on: September 22, 2019
Racial and Ethnic Patterns Observed in Inflammatory Bowel Disease Prevalence, Clinical Burden, and Healthcare
Aarti A Patel1, Shannon Ferrante1, Myrlene Sanon2
1Johnson & Johnson, Titusville, NJ, USA.
Introduction:
Inflammatory bowel disease (IBD) is a chronic, immune-mediated gastrointestinal disorder comprised of Crohn's disease (CD) and ulcerative colitis (UC). Real-world data on racial differences in disease burden, treatment patterns, and healthcare resource utilization (HCRU) remain limited.
Methods:
The retrospective observational study was conducted using Optum's de-identified Clinformatics® Data Mart Database (Optum® CDM) in the US. Data from adult patients with a diagnosis of CD and/or UC between January 1, 2010, and September 30, 2022, were extracted and analyzed to assess the prevalence of IBD, complicated/penetrating CD, and extraintestinal manifestations (EIMs) across different races/ethnicities in the US. The treatment use, HCRU, and symptomatic and psychosocial burden among patients pre-and post-IBD diagnosis were also assessed among patients stratified by race/ethnicity.
Results:
A total of 271,059 patients included in the analysis were predominantly White (76.6%) followed by Black (7.9%), Hispanic (6.1%), and Asian (2.6%). IBD prevalence rose from 0.5% (2010) to 2.2% (2022). In 2022, prevalence was highest among White (2.5%) followed by Black (1.9%), Asian (1.4%), and Hispanic individuals (1.3%). Among patients with CD and UC, respectively, EIM prevalence rose from 38.4% and 31.5% in 2016 to 57.5% and 43.2% in 2022. Corticosteroids and biologics were prescribed to 38.8% and 52.8% of patients with CD and UC post-diagnosis, respectively. IBD-related HCRU increased after diagnosis, particularly among acute care patients, and was highest in Black individuals.
Conclusion:
The results highlight an increased prevalence of IBD among patients from different racial and ethnic backgrounds. The study further provides insights into the IBD-related outcomes, treatment use, and HCRU patterns among diverse racial and ethnic groups and underlines the present unmet need for further research.
Related Concept Videos
01:20Inflammatory Bowel Disease IV: Clinical Manifestations
01:26Inflammatory Bowel Disease I: Introduction
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:25Inflammatory Bowel Disease III: Crohn's Disease
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...